Zdrowie i gospodarka · 16.03.2022
Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Draft Guidance for Industry." The draft guidance document is intended to assist sponsors, including industry and academic sponsors, developing Chimeric Antigen Receptor (CAR) T cell products. The draft guidance includes CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and clinical study design.